A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Grants and Contracts Details

Description

ENGOTEN-6/GOG-3031: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) To compare the progression-free survival (PFS) of treatment with dostarlimab plus carboplatin-paclitaxel to treatment with placebo plus carboplatin-paclitaxel, as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1), in the following: *All subjects with recurrent or primary advanced endometrial cancer *Subjects with microsatellite instability-high (MSI-H) recurrent or primary advanced endometrial cancer
StatusActive
Effective start/end date11/15/192/7/23

Funding

  • Gynecological Oncology Group Foundation Incorporated: $213,275.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.